Long-term survival comparison of first-line pembrolizumab versus pembrolizumab plus chemotherapy for patients with advanced non-small cell lung cancer: A multicenter propensity-matched cohort study
These findings suggest that P-combo showed a durable survival advantage over monotherapy and acceptable TRAEs in patients with PD-L1-positive NSCLC, identifying clinical subgroups most likely to benefit. Prospective randomized trials are warranted to validate these observations and guide optimal first-line treatment strategies.
Authors
- Kinnosuke Matsumoto (ORCID: https://orcid.org/0000-0002-4930-6997)
- Shigeaki Kato (ORCID: https://orcid.org/0000-0002-5564-1695)
- Hirotomo Machiyama (ORCID: https://orcid.org/0009-0002-9155-3956)
- Akihiro Tamiya (ORCID: https://orcid.org/0000-0003-3599-2583)
- Atsushi Kumanogoh (ORCID: https://orcid.org/0000-0003-4749-7117)
- Akio Osa
- Kouji Azuma
- Motohiro Tamiya (ORCID: https://orcid.org/0000-0001-6529-3092)
- Akihiro Tsukaguchi (ORCID: https://orcid.org/0009-0009-6296-4386)
- Satoshi Tanaka (ORCID: https://orcid.org/0000-0002-1854-794X)
- Toshie Niki
- Akito Miyazaki (ORCID: https://orcid.org/0009-0004-7188-674X)
- Yoshito Takeda (ORCID: https://orcid.org/0000-0003-2905-6537)
- Nao Shoshihara (ORCID: https://orcid.org/0009-0008-0576-0312)
- Tomoki Kuge (ORCID: https://orcid.org/0000-0002-9787-1659)
- Kiyohide Komuta
- Yuhei Kinehara
- Takayuki Shiroyama (ORCID: https://orcid.org/0000-0002-2816-9428)
- Yasuhiro Mihashi
- Hidekazu Suzuki (ORCID: https://orcid.org/0000-0002-3855-3140)
- Masahide Mori (ORCID: https://orcid.org/0009-0007-9223-3854)
- Yuki Nishikawa
- Keijiro Yamauchi
Institutions
- Osaka Prefectural Medical Center (JP)
- Osaka City University (JP)
- Toyonaka Municipal Hospital (JP)
- Osaka National Hospital (JP)
- Nishinomiya Municipal Central Hospital (JP)
- Osaka City General Hospital (JP)
- Ikeda Municipal Hospital (JP)
- Toneyama National Hospital (JP)
- Kinki Central Hospital (JP)
- Osaka International Cancer Institute (JP)
- Nippon Medical School Hospital (JP)
- NHO Kinki Chuo Chest Medical Center (JP)
- Osaka International University (JP)
- National Cancer Research Institute (GB)
- Osaka University of Pharmaceutical Sciences (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108835
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Japan Science and Technology Agency